REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 94 filers reported holding REATA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $699,084 | -87.9% | 7,689 | -87.0% | 0.12% | -79.3% |
| Q3 2020 | $5,761,000 | -55.0% | 59,139 | -27.9% | 0.57% | -53.0% |
| Q2 2020 | $12,801,000 | +152.0% | 82,049 | +29.7% | 1.20% | +53.4% |
| Q3 2019 | $5,080,000 | -52.3% | 63,269 | -43.9% | 0.78% | -46.1% |
| Q2 2019 | $10,640,000 | +52.2% | 112,769 | +37.9% | 1.46% | +128.2% |
| Q1 2019 | $6,989,000 | -43.7% | 81,769 | -63.0% | 0.64% | -54.4% |
| Q4 2018 | $12,413,000 | +63.7% | 221,269 | +138.6% | 1.40% | +60.8% |
| Q3 2018 | $7,581,000 | +59.4% | 92,719 | -31.8% | 0.87% | +32.6% |
| Q2 2018 | $4,757,000 | +3.1% | 136,044 | -39.5% | 0.66% | -6.4% |
| Q1 2018 | $4,615,000 | -27.6% | 225,000 | 0.0% | 0.70% | -6.3% |
| Q4 2017 | $6,372,000 | -0.1% | 225,000 | +9.8% | 0.75% | -17.8% |
| Q3 2017 | $6,376,000 | – | 205,000 | – | 0.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |